A CASE REPORT: ZOLEDRONIC ACID INDUCED JAW OSTEONECROSIS IN PATIENT WITH BONE METASTASIS A RELATIVELY RARE SIDE EFFECT

Introduction: Jaw osteonecrosis (JON) is an infrequent side effect observed in patients receiving bisphosphonate therapy for bone maintenance during bone metastasis conditions. Nitrogen based bisphosphonates(NBBP) like Zoledronic acid when given intravenous (IV) infusion have potent ability to develop jaw osteonecrosis as compared to oral therapy. For optimal therapeutic effects and patient compliance perennial  administration of Zoledronic acid is preferred.

Case Presentation: we report a case of 80-year-old woman suffering from endometrial cancer with bone metastasis developed Jaw osteonecrosis( JON  )after consecutive cycles Zoledronic acid infusion. On Examination revealed the  Classical signs of Jaw osteonecrosis(JON)On reporting physician examined and  discontinued the zoledronate infusion.

Conclusion: Jaw osteonecrosis(JON) occurs as a  consequence of  zoledronate perennial infusions. Risk is more in persons with poor oral hygiene due to infections.

Key words: Zoledronic acid, Jaw osteonecrosis, Perennial infusion, Poor oral hygiene.